NeuroBlate System
Commercial- Indications
- Brain tumors, Drug-resistant epilepsy, Radiation necrosis
Company intelligence / Profile preview
The NeuroBlate System has been used in over 4,000 patients with published data supporting its safety and efficacy for minimally invasive ablation of brain tumors and drug-resistant epilepsy. It has FDA clearance for certain uses and continues to be evaluated in clinical studies such as FLARE for refractory epilepsy. Recent publications include the largest cohort to date of LITT with NeuroBlate® System for meningioma.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Monteris Medical.